http://medicineworld.org/news/ovariannews.html MedicineWorld.Org brings daily ovarian cancer news from various sources to keep you updated on the latest events in the world on this topic. Medicineworld heart watch news service is the most comprehensive heart watch news service on the internet. We keep an archive of previous few days of news on this site. Please go down through the list to find the older news items. Wed, 06 Jul 2011 02:17:04 GMT en-us http://medicineworld.org/images/ovaries.jpg http://medicineworld.org/news/ovariannews.html 108 87 http://medicineworld.org/stories/lead/7-2011/biomechanics-of-ovarian-cells.html http://medicineworld.org/stories/lead/7-2011/biomechanics-of-ovarian-cells.html Wed, 06 Jul 2011 02:17:04 GMT Using ovarian surface epithelial cells from mice, scientists from Virginia Tech have released findings from a study that they believe will help in cancer risk evaluation, cancer diagnosis, and therapy efficiency in a technical journal: Nanomedicine http://www.nanomedjournal.com/article/S1549-9634%2811%2900184-5/abstract........ ]]> http://medicineworld.org/stories/lead/12-2010/biological-diversity-of-ovarian-cancer.html http://medicineworld.org/stories/lead/12-2010/biological-diversity-of-ovarian-cancer.html Wed, 06 Jul 2011 02:17:04 GMT Cancer prevention experts have long been frustrated by the lack of a meaningful way to screen women for ovary cancer. It is a relatively rare disease that often progresses with few symptoms until it is too late for potentially curative therapys, and elevated values of the most usually used biomarker used in screening, CA125, are also correlation to other disorders........ ]]> http://medicineworld.org/stories/lead/10-2010/investigational-ovarian-cancer-drug-shows-promise.html http://medicineworld.org/stories/lead/10-2010/investigational-ovarian-cancer-drug-shows-promise.html Wed, 06 Jul 2011 02:17:04 GMT A drug being developed as a therapy for ovary cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial, an international research group has reported. Dr Ursula Matulonis from Dana-Farber Cancer Institute in the USA reported the results of the single-agent trial of the drug, called MLN8237, in a poster at the 35th Congress of the European Society for Medical Oncology (ESMO)........ ]]> http://medicineworld.org/stories/lead/9-2010/new-genetic-links-to-ovarian-cancer-risk.html http://medicineworld.org/stories/lead/9-2010/new-genetic-links-to-ovarian-cancer-risk.html Wed, 06 Jul 2011 02:17:04 GMT An international consortium of researchers has discovered new genetic variants in five regions of the genome that affect the risk of ovary cancer in the general population, as per two separate studies published recently (Sunday), online in Nature Genetics The consortium, including researchers from the U.S., Europe, Canada and Australia, based the new work on their earlier research comparing 10,283 women with ovary cancer to 13,185 women without the disease. That effort had found a stretch of DNA on chromosome 9 containing single DNA letter variations (SNPs) linked to ovary cancer risk........ ]]> http://medicineworld.org/stories/lead/8-2010/new-ovarian-cancer-tests-have-high-accuracy.html http://medicineworld.org/stories/lead/8-2010/new-ovarian-cancer-tests-have-high-accuracy.html Wed, 06 Jul 2011 02:17:04 GMT Researchers at the Georgia Institute of Technology have attained very promising results on their initial investigations of a new test for ovary cancer. Using a new technique involving mass spectrometry of a single drop of blood serum, the test correctly identified women with ovary cancer in 100 percent of the patients tested. The results can be found online in the journal Cancer Epidemiology, Biomarkers, and Prevention Research........ ]]> http://medicineworld.org/stories/lead/7-2010/advances-in-chemotherapy-of-ovarian-patients.html http://medicineworld.org/stories/lead/7-2010/advances-in-chemotherapy-of-ovarian-patients.html Wed, 06 Jul 2011 02:17:04 GMT Investigators at the Translational Genomics Research Institute (TGen) have discovered a way that may help ovary cancer patients who no longer respond to conventional chemotherapy. A scientific paper that would be reported in the recent issue of the journal Gynecologic Oncology describes how the inhibition of a protein, CHEK1, appears to be an effective element to incorporate into therapies for women with ovary cancer........ ]]> http://medicineworld.org/stories/lead/6-2010/early-detection-of-ovarian-cancer.html http://medicineworld.org/stories/lead/6-2010/early-detection-of-ovarian-cancer.html Wed, 06 Jul 2011 02:17:04 GMT Despite a number of research advances, ovary cancer remains lethal in a majority of cases, due to late diagnosis of the disease. In a newly released study, Dr. Joshua LaBaer of the Biodesign Institute at Arizona State University, along with Arturo Ramirez and Paul Lampe, scientists at the Fred Hutchinson Cancer Research Center in Seattle, used a novel method for identifying biomarkers-proteins in blood that can identify ovary cancer before symptoms appear........ ]]> http://medicineworld.org/stories/lead/6-2010/chemotherapy-of-late-stage-ovarian-cancer.html http://medicineworld.org/stories/lead/6-2010/chemotherapy-of-late-stage-ovarian-cancer.html Wed, 06 Jul 2011 02:17:04 GMT The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovary cancer. In an upcoming issue of the journal Cancer (online today), Indiana University scientists report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of therapy. One patient experienced complete resolution of tumor tissue for a period of time........ ]]> http://medicineworld.org/stories/lead/6-2010/new-treatment-regimen-for-ovarian-cancer.html http://medicineworld.org/stories/lead/6-2010/new-treatment-regimen-for-ovarian-cancer.html Wed, 06 Jul 2011 02:17:04 GMT Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovary cancer and then continuing one of the majortenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new therapy regimen saw no worsening of their disease for 14.1 months, in comparison to 10.3 months for women receiving standard treatment........ ]]> http://medicineworld.org/stories/lead/5-2010/ca-125-change-over-time.html http://medicineworld.org/stories/lead/5-2010/ca-125-change-over-time.html Wed, 06 Jul 2011 02:17:04 GMT Evaluating its change over time, CA-125, the protein long-recognized for predicting ovary cancer recurrence, now shows promise as a screening tool for early-stage disease, as per scientists at The University of Texas MD Anderson Cancer Center. The findings were presented today by Karen Lu, M.D., professor in MD Anderson's Department of Gynecologic Oncology, in advance of the American Society of Clinical Oncology (ASCO) annual meeting. If a larger study shows survival benefit, the simple blood test could offer a much-needed screening tool to detect ovary cancer in it early stages - even in the most aggressive forms - in post-menopausal women at average risk for the disease........ ]]> http://medicineworld.org/stories/lead/3-2010/elective-removal-of-ovaries-during-hysterectomy.html http://medicineworld.org/stories/lead/3-2010/elective-removal-of-ovaries-during-hysterectomy.html Wed, 06 Jul 2011 02:17:04 GMT Removal of the ovaries (bilateral oophorectomy) while performing a hysterectomy is common practice to prevent the subsequent development of ovary cancer. This prophylactic procedure is performed in 55% of all U.S. women having a hysterectomy, or approximately 300,000 times each year. An article in the March/recent issue of The Journal of Minimally Invasive Gynecology suggests that this procedure may do more harm than good........ ]]> http://medicineworld.org/stories/lead/2-2010/fat-tissue-in-women-with-polycystic-ovary-syndrome.html http://medicineworld.org/stories/lead/2-2010/fat-tissue-in-women-with-polycystic-ovary-syndrome.html Wed, 06 Jul 2011 02:17:04 GMT Fat tissue in women with Polycystic Ovary Syndrome produces an inadequate amount of the hormone that regulates how fats and glucose are processed, promoting increased insulin resistance and inflammation, glucose intolerance, and greater risk of diabetes and heart disease, as per a research studyconducted at the Center for Androgen-Related Research and Discovery at Cedars-Sinai Medical Center........ ]]> http://medicineworld.org/stories/lead/7-2009/chemo-directly-to-ovarian-cancer-cells.html http://medicineworld.org/stories/lead/7-2009/chemo-directly-to-ovarian-cancer-cells.html Wed, 06 Jul 2011 02:17:04 GMT With a novel therapeutic delivery system, a research team led by researchers at The University of Texas M. D. Anderson Cancer Center has successfully targeted a protein that is over-expressed in ovary cancer cells. Using the EphA2 protein as a molecular homing mechanism, chemotherapy was delivered in a highly selective manner in preclinical models of ovary cancer, the scientists report in the July 29 issue of the Journal of the National Cancer Institute....... ]]> http://medicineworld.org/stories/lead/4-2009/against-recurrent-gynecologic-cancers.html http://medicineworld.org/stories/lead/4-2009/against-recurrent-gynecologic-cancers.html Wed, 06 Jul 2011 02:17:04 GMT Recurrent and metastatic endometrial and ovary cancers can be notoriously difficult to treat: They have spread to other organs and typically have developed resistance to chemotherapy; and patients already heavily treated with chemotherapy may not be able to endure more chemo. Now, physicians at Albert Einstein College of Medicine of Yeshiva University have shown that a combination of two chemotherapy drugs not only produced clinical benefit for such patients but were also well tolerated. The findings are published online in the journal Gynecologic Oncology....... ]]> http://medicineworld.org/stories/lead/4-2009/ovarian-cancer-screening.html http://medicineworld.org/stories/lead/4-2009/ovarian-cancer-screening.html Wed, 06 Jul 2011 02:17:04 GMT The only available screening tests for ovary cancer fail to catch early signs of the disease and often result in unnecessary surgery, said scientists at the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center. The newly released study looked at a screening regimen that combines ultrasound and a blood test for CA-125, a marker for women's cancer........ ]]>